Our data thus reveal that prostate cancer CSC tumorigenicity is driven by a novel function of Gβγ signaling, and that targeting Gβγ signaling may be a new way to eliminate these cells to block tumor progression. The gene discussed is CFB; the disease is Familial prostate cancer.